source
- AstraZeneca proposes $10 billion purchase of Rhythm Pharmaceuticals, sparking possible bidding warAstraZeneca has reportedly made an offer of about $10 billion to buy Rhythm Pharmaceuticals, a company focused on rare obesity disorders. Analysts from at least three research groups say the propo…
- Evommune pays $30 million to Hinova for rights to develop oral VAV1 molecular glue degrader EVO570 outside ChinaEvommune announced a licensing agreement with Chinese firm Hinova Pharmaceuticals, paying $30 million upfront for access to a preclinical molecular glue program. The agreement gives Evommune the r…